770-771 / 2437
Brain mets: a particular challenge?
• Novel ALK inhibitors: ceritinib and alectinib which are
both active against ALK-positive NSCLC
• Ceritinib concentration in the CNS may reach
approximately 13% of systemic levels in preclinical
models
Shaw et al. New Engl J Med 2014
Gadgeel et al. Lancet Oncol 2014
Kim et al. ASCO 2014
=> Crizotinib: very limited CNS penetrance (< 1%)
Costa et al. J Clin Oncol 2011